11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Spatial Access to Vaccines for Children Providers in South Carolina: Implications for HPV Vaccination

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Panel A shows the location of VFC providers by rural and urban Zip Code Tabulation Areas (ZCTAs). Panel B shows the age-eligible population for the VFC programs by tertiles. Panel C shows spatial accessibility by tertile of accessibility score for both rural and urban ZCTAs. Accessibility was defined as supply (ie, VFC provider locations) of and demand for services (ie, children and adolescents age-eligible for the VFC program) within a specified catchment area (ie, 30 minutes’ drive time). Panel D shows spatial accessibility cold spots and hot spots (areas of low access [cold spots] and high access [hot spots]) across ZCTAs. Sources: South Carolina Department of Health and Environmental Control (VFC data, 2019) and the American Community Survey (2013–2017). Alternate text In panel A, rural ZCTAs are in the northeast, southeast, and southwest parts of the state. The central and coastal parts of the state were more urban, and the northwestern part of the state has a mix of rural and urban areas. More VFC locations were in urban ZCTAs. The locations in rural areas often are much further apart and fewer in number in other locations. In panel B, the age-eligible population (number of children aged <18 years) for VFC programs in each ZCTA is noted by tertile: 0 to 506, 507 to 2,589, and 2,590 to 21,113 persons. Larger age-eligible populations are in the northern ZCTAs, while the southern part of the state has smaller age-eligible populations. In panel C, spatial accessibility scores, as calculated by using the 2-step floating catchment area method, are shown as high, moderate, or low for both urban and rural areas. Many rural areas are shown to have high access, while large sections of urban areas have low access. In panel D, cold spots and hot spots are shown with 99% confidence, 95% confidence, and 90% confidence. In most of the state there is no significant difference between urban and rural ZCTAs regarding access to VFC programs. The few hot spots with 99% confidence and 95% confidence are mostly in the southern rural areas that border urban areas in the state. The cold spots with 90% confidence are in urban areas mostly in the central part of the state; there were no cold spots with 95% or 99% confidence. Background The Advisory Committee on Immunization Practices recommends routine human papillomavirus (HPV) vaccination for male and female adolescents aged 11 or 12 years, beginning as early as age 9, with catch-up vaccination for all people through age 26, and shared clinical decision making before vaccination decisions for those aged 27 to 45 (1,2). Although uptake of HPV vaccination has increased since its initial recommendation (2006 for girls; 2011 for boys), rural populations have lower rates of initiation and completion compared with their urban counterparts, particularly in the southern United States (3). To improve rural HPV vaccination rates, several policy recommendations have been made, including increasing access to the Vaccines for Children (VFC) program through federally qualified health centers, rural health clinics, health departments, and other settings, including pharmacies (4). The VFC program is a federally funded program that provides vaccines at no cost for certain populations (5). Children through age 18 years who are uninsured, underinsured, Medicaid eligible, or of American Indian/Alaska Native descent can access free HPV vaccination through VFC-enrolled providers. In South Carolina, rural residents aged 13 to 17 years have lower rates of HPV vaccination initiation (62.2% in 2018) compared with their urban counterparts (79.8% in metropolitan central cities vs 66.8% in metropolitan noncentral cities) (6). To better understand potential drivers of this rural–urban disparity, our objective was to examine spatial access to VFC-enrolled clinics across rural and urban areas of South Carolina. Data Sources and Map Logistics We obtained and geocoded addresses of publicly accessible VFC-enrolled providers from the South Carolina Department of Health and Environmental Control. Nonpublicly accessible VFC providers (eg, juvenile detention centers) were excluded. We also obtained Zip Code Tabulation Area–level (ZCTA, which are geographic approximations of zip codes) population estimates of persons under the age of 18 (ie, age grouping of available data that are most congruent with VFC eligibility criteria) from the 2013–2017 American Community Survey (7). We then performed the 2-step floating catchment area (2SFCA) method in ArcGIS 10.5.1 (Esri) to determine spatial access to VFC providers at the ZCTA–level. The 2SFCA method considers the supply (ie, VFC provider locations) of and demand for services (ie, children and adolescents) within a specified catchment area (ie, 30 minutes’ drive time) to generate a score indicating access to VFC providers for each ZCTA. Thus, for example, a ZCTA may have many VFC providers, but if the 30-minute catchment area has a large population, it will have a smaller access score compared with ZCTAs with fewer providers but a relatively smaller population. Potential values can range from 0 (no access within 30 minutes) to 1 (an improbable 1:1 VFC provider:child ratio). Additional details about this approach are detailed elsewhere (8). We calculated travel distance from the centroid of each ZCTA to the nearest VFC provider, which enables us to determine proximity to VFC providers but does not account for potential demand for services. ZCTAs were categorized as rural or urban using rural–urban commuting area primary codes, with a code of 4 or more categorized as rural (9). We then performed Optimized Hot Spot Analysis by using the Getis-Ord Gi* tool (10). This statistic identifies where areas of high access (hot spots) and low access (cold spots) are clustered, while adjusting for false discovery rates and spatial dependence. We examined rural–urban differences in VFC providers by type (eg, public health department), spatial accessibility scores, distance to the nearest VFC provider, and hot spots and cold spots by using independent t tests and χ2 analyses for continuous and categorical variables, respectively. Highlights South Carolina has 493 public VFC providers across rural and urban ZCTAs (panel A). Rural and urban VFC providers varied by type, with the largest proportion of rural providers (41.1%) at federally designated health care centers and the largest proportion of urban providers (55.6%) at private clinics (P < .001) (Table 1). Table 1 Vaccines for Children (VFC) Provider Type Across Rural and Urban Designated Zip Code Tabulation Areas (ZCTAs), South Carolinaa Provider Type Rural ZCTA (n = 151), No. (%) Urban ZCTA (n = 342), No. (%) P Value Hospitals 10 (6.6) 24 (7.0) <.001 Private clinics 41 (27.2) 190 (55.6) Federally designated health care centersb 62 (41.1) 71 (20.8) Public health departments 27 (17.9) 28 (8.2) Not specified 11 (7.3) 29 (8.5) a Analysis using data from the South Carolina Department of Health and Environmental Control (VFC data, 2019) and the American Community Survey (2013–2017). b Includes federally qualified health centers, rural health clinics, and other community health centers. Panel B shows the number of children under age 18 within each ZCTA, by tertile. Panel C shows rural and urban ZCTAs by tertiles of access scores. Panel D shows the findings of the Getis-Ord Gi* analysis of these data, indicating hot spots (ie, clusters of high access) primarily toward the southernmost rural tip of the state and toward the northeastern part of the state. Rural ZCTAs had higher mean access scores compared with urban ZCTAs (0.000548 vs 0.000419, P < .001) (Table 2). There was no difference in distance to the nearest VFC provider across rural and urban ZCTAs (7.50 vs 6.47 miles, P = .06). A higher proportion of rural ZCTAs (16.0%) was in hot spots compared with urban ZCTAs (4.7%) (P < .001). Table 2 Spatial Access to Vaccines for Children (VFC) Provider Locations by Rural–Urban Designation Across Zip Code Tabulation Areas, South Carolina Designation Rural (n = 125) Urban (n = 299) P Value Clusters typea, n (%) Hot spot 20 (16.0) 14 (4.7) <.001b Cold spot 1 (0.8) 8 (2.7) Nonsignificant 104 (83.2) 277 (92.6) Access scorec, mean (SD) 0.000548 (0.000357) 0.000419 (0.000294) <.001d Distance to the nearest VFC provider, mean (SD), miles 7.50 (4.92) 6.47 (5.04) .06d a Analysis using data from the South Carolina Department of Health and Environmental Control (VFC data, 2019) and the American Community Survey (2013–2017). Clusters are identified as areas of high access (hot spots) and low access (cold spots). b P value from χ2 test. c The supply (ie, VFC provider locations) of and demand for services (ie, children and adolescents) within a specified catchment area (ie, 30 minutes’ drive time). d From independent t test. Actions We found that children and adolescents in rural ZCTAs in South Carolina have greater access to VFC providers than those in urban ZCTAs, as demonstrated by higher mean accessibility scores across rural ZCTAs, comparable distances to the nearest VFC provider in urban ZCTAs, and a higher proportion of rural ZCTAs in hot spots. This information suggests that lower HPV vaccination initiation and completion rates in rural South Carolina are likely due to factors other than limited spatial access to VFC providers. Previous studies found lower levels of HPV awareness and knowledge among rural residents compared with urban residents (11). Additionally, providers are less likely to engage in collaborative communication about HPV and HPV vaccination with rural parents (11). Educational interventions, awareness campaigns, and enhanced provider training may be effective ways to improve uptake, especially considering the relatively high availability of VFC programs in many rural areas in the state (12). Identifying clusters with limited access to VFC providers may help health care systems, public health departments, and policy makers engage in targeted efforts to increase VFC enrollment and thereby expand access to vaccination for vulnerable children and adolescents. Reducing out-of-pocket costs associated with vaccination, implementing vaccination programs in schools and child care centers, and offering vaccinations through home health visits and at pharmacies are also recommended, evidence-based strategies (13,14). Previous studies have shown the utility of using GIS approaches to identify low access areas and target them for additional programs (15). The Community Preventive Services Task Force has also identified multiple provider-level or systems-level strategies to increase vaccine uptake, such as the use of provider reminder systems and standing orders (16). Understanding the distribution and diversity of VFC providers across rural and urban areas may help inform planning for and delivery of these types of interventions. We found that more than half of rural VFC providers are in federally designated community-based clinics. Community-based clinics are important for expanding access to HPV vaccination for rural populations, and are optimal sites for implementing systems, tools, and protocols that improve vaccination rates (4).

          Related collections

          Most cited references9

          • Record: found
          • Abstract: not found
          • Article: not found

          Measures of spatial accessibility to health care in a GIS environment: synthesis and a case study in the Chicago region

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices

            Introduction Vaccination against human papillomavirus (HPV) is recommended to prevent new HPV infections and HPV-associated diseases, including some cancers. The Advisory Committee on Immunization Practices (ACIP)* routinely recommends HPV vaccination at age 11 or 12 years; vaccination can be given starting at age 9 years. Catch-up vaccination has been recommended since 2006 for females through age 26 years, and since 2011 for males through age 21 years and certain special populations through age 26 years. This report updates ACIP catch-up HPV vaccination recommendations and guidance published in 2014, 2015, and 2016 ( 1 – 3 ). Routine recommendations for vaccination of adolescents have not changed. In June 2019, ACIP recommended catch-up HPV vaccination for all persons through age 26 years. ACIP did not recommend catch-up vaccination for all adults aged 27 through 45 years, but recognized that some persons who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination in this age range; therefore, ACIP recommended shared clinical decision-making regarding potential HPV vaccination for these persons. Background HPV is a common sexually transmitted infection, with HPV acquisition generally occurring soon after first sexual activity ( 1 ). Most HPV infections are transient and asymptomatic. Persistent infections with high-risk (oncogenic) HPV types can lead to development of cervical, anal, penile, vaginal, vulvar, and oropharyngeal cancers, usually after several decades ( 1 ). Most new HPV infections occur in adolescents and young adults. Although most sexually active adults have been exposed to HPV ( 4 ), new infections can occur with a new sex partner ( 5 ). Three prophylactic HPV vaccines are licensed for use in the United States: 9-valent (9vHPV, Gardasil 9, Merck), quadrivalent (4vHPV, Gardasil, Merck), and bivalent (2vHPV, Cervarix, GlaxoSmithKline) ( 6 – 8 ). As of late 2016, only 9vHPV is distributed in the United States. The majority of HPV-associated cancers are caused by HPV 16 or 18, types targeted by all three vaccines. In addition, 4vHPV and 9vHPV target HPV 6 and 11, types that cause anogenital warts. 9vHPV also protects against five additional high-risk types: HPV 31, 33, 45, 52, and 58. In October 2018, using results from 4vHPV clinical trials in women aged 24 through 45 years, and bridging immunogenicity and safety data in women and men, the Food and Drug Administration expanded the approved age range for 9vHPV use from 9 through 26 years to 9 through 45 years in women and men ( 6 ). In June 2019, after reviewing evidence related to HPV vaccination of adults, ACIP updated recommendations for catch-up vaccination and for vaccination of adults older than the recommended catch-up age. Methods During April 2018–June 2019, the ACIP HPV Vaccines Work Group held at least monthly conference calls to review and discuss relevant scientific evidence regarding adult HPV vaccination using the Evidence to Recommendations framework. (https://www.cdc.gov/vaccines/acip/recs/grade/downloads/ACIP-evidence-rec-frame-508.pdf). The Work Group evaluated the quality of evidence for efficacy, safety, and effectiveness for HPV vaccination for primary prevention of HPV infection and HPV-related disease using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (https://www.cdc.gov/vaccines/acip/recs/grade/about-grade.html). Scientific literature published during January 1, 2006–October 18, 2018, was searched to identify clinical trials of any licensed HPV vaccine in adults aged 27 through 45 years. Detailed search methods and results for the GRADE tables are available at https://www.cdc.gov/vaccines/acip/recs/grade/HPV-adults.html. Benefits were based on per-protocol analyses of vaccine efficacy; immunogenicity data were also considered. Harms were any vaccine-related serious adverse events. Of 1,388 references identified, 100 were selected for detailed review, and 16 publications were included in GRADE tables presented at the October 2018 ACIP meeting; tables were updated in June 2019 to include new results from a 9vHPV trial. At the June 2019 ACIP meeting, two policy issues were considered: 1) harmonization of catch-up vaccination for all persons through age 26 years, and 2) vaccination of adults aged >26 years. Two Evidence to Recommendations documents were developed (https://www.cdc.gov/vaccines/acip/recs/grade/HPV-harmonization-etr.html ) ( https://www.cdc.gov/vaccines/acip/recs/grade/HPV-adults-etr.html) and presented along with proposed recommendations; after a public comment period, ACIP members voted unanimously to harmonize catch-up vaccination recommendations across genders for all persons through age 26 years. ACIP members also voted 10–4 in favor of shared clinical decision-making for adults aged 27 through 45 years, recognizing that some persons who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination in this age range. Summary of Key Findings Vaccine efficacy and safety. Data were considered from 11 clinical trials of 9vHPV, 4vHPV, and/or 2vHPV in adults aged 27 through 45 years, along with supplemental bridging immunogenicity data. In per-protocol analyses from three trials, 4vHPV and 2vHPV demonstrated significant efficacy against a combined endpoint of persistent vaccine-type HPV infections, anogenital warts, and cervical intraepithelial neoplasia (CIN) grade 1 (low-grade lesions) or worse. In nine trials, seroconversion rates to vaccine-type HPV after 3 doses of any HPV vaccine were 93.6%–100% at 7 months after the first dose. Overall evidence on benefits was GRADE evidence level 2, for moderate-quality evidence. In nine trials, few serious adverse events and no vaccine-related deaths were reported. Overall evidence on harms was also GRADE evidence level 2, for moderate-quality evidence. In the efficacy trial that was the basis for 9vHPV licensure for adults through age 45 years, per-protocol efficacy of 4vHPV among women aged 24 through 45 years was 88.7% (95% confidence interval [CI] = 78.1–94.8), and intention-to-treat efficacy was 47.2% (95% CI = 33.5–58.2) against a combined endpoint of persistent infections, extragenital lesions, and CIN 1+ related to HPV types 6, 11, 16, or 18 ( 9 ). HPV burden of disease and impact of the vaccination program in the United States. Approximately 33,700 cancers are caused by HPV in the United States each year, including 12,900 oropharyngeal cancers among men and women, 10,800 cervical cancers among women, and 6,000 anal cancers among men and women; vaginal, vulvar, and penile cancers are less common ( 10 ). HPV vaccination for adolescents has been routinely recommended for females since 2006 and for males since 2011 ( 1 ). The existing HPV vaccination program for adolescents has the potential to prevent the majority of these cancers. Mean age at acquisition of causal HPV infection for cancers is unknown, but is estimated to be decades before cancer is diagnosed. In 2017, coverage with ≥1 dose of HPV vaccine was 65.5% among adolescents aged 13 through 17 years ( 11 ). Although coverage with the recommended number of doses remains below the Healthy People 2020 target of 80% for adolescents ( 12 ), the U.S. HPV vaccination program has resulted in significant declines in prevalences of vaccine-type HPV infections, anogenital warts, and cervical precancers ( 13 ). For example, prevalences of 4vHPV vaccine-type infection during 2013–2016, compared with those of the prevaccine era, declined from 11.5% to 1.8% among females aged 14 through 19 years and from 18.5% to 5.3% among females aged 20 through 24 years ( 14 ). In addition, declines have been observed among unvaccinated persons, suggesting protective herd effects ( 15 ). Health economic analyses. Five health economic models of HPV vaccination in the United States were reviewed ( 16 ). The cost effectiveness ratio for the current HPV vaccination program ranged from cost-saving to approximately $35,000 per quality-adjusted life year (QALY) gained ( 16 ). In the context of the existing vaccination program, the incremental cost per QALY for expanding male vaccination through age 26 years was $178,000 in a subset of analyses in one of the five models reviewed using more favorable model assumptions for adult vaccination ( 16 ). In the context of the existing program, expanding vaccination to adults through age 45 years would produce relatively small additional health benefits and less favorable cost-effectiveness ratios. The incremental cost per QALY for also vaccinating adults through age 30 or 45 years exceeded $300,000 in four of five models ( 16 ). Variation in results across models was likely due to uncertainties about HPV natural history, such as prevalence of immunity after clearance of natural infections, and level of herd protection from the existing program. Under the existing program, in a subset of analyses in one of the five models reviewed using more favorable model assumptions for adult vaccination, the number needed to vaccinate (NNV) to prevent one case of anogenital warts, CIN grade 2 or worse (high-grade lesions), or cancer would be 9, 22, and 202, respectively. For expanding recommendations for males through age 26 years to harmonize catch-up vaccination across genders, these NNV would be 40, 450, and 3,260, respectively. For expanding recommendations to include adults through age 45 years, these NNV would be 120, 800, and 6,500, respectively ( 16 ). Rationale Adolescents remain the most important focus of the HPV vaccination program in the United States. Recommendations harmonized across genders will simplify the immunization schedule and be more feasible to implement. HPV vaccination is most effective when given before exposure to any HPV, as in early adolescence ( 1 – 3 ). Clinical trials have indicated that HPV vaccines are safe and effective against infection and disease attributable to HPV vaccine types that recipients are not infected with at the time of vaccination. Because HPV acquisition generally occurs soon after first sexual activity, vaccine effectiveness will be lower in older age groups because of prior infections. Some previously exposed adults will have developed natural immunity already. Exposure to HPV decreases among older age groups. Evidence suggests that although HPV vaccination is safe for adults aged 27 through 45 years, population benefit would be minimal; nevertheless, some adults who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination in this age range. Recommendations Children and adults aged 9 through 26 years. HPV vaccination is routinely recommended at age 11 or 12 years; vaccination can be given starting at age 9 years. Catch-up HPV vaccination is recommended for all persons through age 26 years who are not adequately vaccinated. † Adults aged >26 years. Catch-up HPV vaccination is not recommended for all adults aged >26 years. Instead, shared clinical decision-making regarding HPV vaccination is recommended for some adults aged 27 through 45 years who are not adequately vaccinated. (Box). HPV vaccines are not licensed for use in adults aged >45 years. BOX Considerations for shared clinical decision-making regarding human papillomavirus (HPV) vaccination of adults aged 27 through 45 years Ideally, HPV vaccination should be given in early adolescence because vaccination is most effective before exposure to HPV through sexual activity. For adults aged 27 through 45 years who are not adequately vaccinated,* clinicians can consider discussing HPV vaccination with persons who are most likely to benefit. HPV vaccination does not need to be discussed with most adults aged >26 years. HPV is a very common sexually transmitted infection. Most HPV infections are transient and asymptomatic and cause no clinical problems. Although new HPV infections are most commonly acquired in adolescence and young adulthood, some adults are at risk for acquiring new HPV infections. At any age, having a new sex partner is a risk factor for acquiring a new HPV infection. Persons who are in a long-term, mutually monogamous sexual partnership are not likely to acquire a new HPV infection. Most sexually active adults have been exposed to some HPV types, although not necessarily all of the HPV types targeted by vaccination. No clinical antibody test can determine whether a person is already immune or still susceptible to any given HPV type. HPV vaccine efficacy is high among persons who have not been exposed to vaccine-type HPV before vaccination. Vaccine effectiveness might be low among persons with risk factors for HPV infection or disease (e.g., adults with multiple lifetime sex partners and likely previous infection with vaccine-type HPV), as well as among persons with certain immunocompromising conditions. HPV vaccines are prophylactic (i.e., they prevent new HPV infections). They do not prevent progression of HPV infection to disease, decrease time to clearance of HPV infection, or treat HPV-related disease. * Dosing schedules, intervals, and definitions of persons considered adequately vaccinated have not changed. Administration. Dosing schedules, intervals, and definitions of persons considered adequately vaccinated have not changed ( 3 ).No prevaccination testing (e.g., Pap or HPV testing) is recommended to establish the appropriateness of HPV vaccination. Cervical cancer screening. Cervical cancer screening guidelines and recommendations should be followed ( 17 ). Special populations and medical conditions. These recommendations for children and adults aged 9 through 26 years and for adults aged >26 years apply to all persons, regardless of behavioral or medical risk factors for HPV infection or disease. § For persons who are pregnant, HPV vaccination should be delayed until after pregnancy; however, pregnancy testing is not needed before vaccination. Persons who are breastfeeding or lactating can receive HPV vaccine. Recommendations regarding HPV vaccination during pregnancy or lactation have not changed ( 1 ). Future Research and Monitoring Priorities CDC continues to monitor safety of HPV vaccines and impact of the vaccination program on HPV-attributable outcomes, including prevalences of HPV infections, anogenital warts, cervical precancers, and cancers. ACIP reviews relevant data as they become available and updates vaccine policy as needed. Summary What is already known about this topic? Vaccination against human papillomavirus (HPV) is routinely recommended at age 11 or 12 years. Catch-up recommendations apply to persons not vaccinated at age 11 or 12 years. What is added by this report? After reviewing new evidence, CDC updated HPV vaccination recommendations for U.S. adults. What are the implications for public health practice? Routine recommendations for HPV vaccination of adolescents have not changed. Catch-up HPV vaccination is now recommended for all persons through age 26 years. For adults aged 27 through 45 years, public health benefit of HPV vaccination in this age range is minimal; shared clinical decision-making is recommended because some persons who are not adequately vaccinated might benefit.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices.

              Vaccination against human papillomavirus (HPV) is recommended to prevent HPV infections and HPV-associated diseases, including cancers. Routine vaccination at age 11 or 12 years has been recommended by the Advisory Committee on Immunization Practices (ACIP) since 2006 for females and since 2011 for males (1,2). This report provides recommendations and guidance regarding use of HPV vaccines and updates ACIP HPV vaccination recommendations previously published in 2014 and 2015 (1,2). This report includes new recommendations for use of a 2-dose schedule for girls and boys who initiate the vaccination series at ages 9 through 14 years. Three doses remain recommended for persons who initiate the vaccination series at ages 15 through 26 years and for immunocompromised persons.
                Bookmark

                Author and article information

                Journal
                Prev Chronic Dis
                Prev Chronic Dis
                PCD
                Preventing Chronic Disease
                Centers for Disease Control and Prevention
                1545-1151
                2020
                24 December 2020
                : 17
                : E163
                Affiliations
                [1 ]Rural and Minority Health Research Center, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina
                [2 ]Big Data Health Science Center, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina
                [3 ]Department of Psychology, College of Arts and Sciences, University of South Carolina, Columbia, South Carolina
                [4 ]South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina
                [5 ]Department of Health Promotion, Education and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina
                [6 ]Cancer Prevention and Control Program, University of South Carolina, Columbia, South Carolina
                [7 ]College of Nursing, University of South Carolina, Columbia, South Carolina
                [8 ]Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina
                Author notes
                Corresponding Author: Whitney E. Zahnd, PhD, Rural and Minority Health Research Center, Arnold School of Public Health, University of South Carolina, 220 Stoneridge Dr, Ste 204, Columbia, SC 29210. Telephone: 803-576-6057. Email: zahnd@ 123456mailbox.sc.edu .
                Article
                20_0300
                10.5888/pcd17.200300
                7784554
                33357307
                d6480d6f-17d0-4349-83e9-8470a4187f5e
                Copyright @ 2020

                Preventing Chronic Disease is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.

                History
                Categories
                GIS Snapshots
                Peer Reviewed

                Health & Social care
                Health & Social care

                Comments

                Comment on this article